|Market Cap (Intraday)||748.26M|
|2yr Forward PE||N/A|
Vaxart, Inc. Stock, NASDAQ:VXRT
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.